Developing a Standardized Definition for Disease “Flare” in Rheumatoid Arthritis (OMERACT 9 Special Interest Group)

Objective. Traditional outcome measures in randomized controlled trials (RCT) include well-established response criteria as well as ACR EULAR responses using Disease Activity Score 44 (DAS44)/DAS28 to assess improvement; however, a measure to assess worsening of disease has yet to be developed. This special interest group (SIG) was established to develop an evidence-based, consensus-driven standard definition of “flare” in rheumatoid arthritis (RA). Methods. At OMERACT 8, the need for a standardized definition of RA flare was recognized; interested individuals developed a proposal to form a SIG. A literature review was performed to identify publications and abstracts with flare definitions applied in RA, JIA, and lupus RCT as well as concerning patient perspectives on disease worsening. A SIG was held at OMERACT 9 with breakout sessions for patients and investigators. Results. The RA flare SIG was attended by about 120 participants, including 11 patients. Patients and investigators held separate breakout sessions to discuss various aspects of disease worsening. The following consensus was obtained at OMERACT 9: a working definition of flare should indicate worsening of disease activity (88%), persistence, and duration as critical elements (77%), and consideration of change or increase in therapy (74%). Conclusion. A working definition of RA flare was developed based on these votes: flare is any worsening of disease activity that would, if persistent, in most cases lead to initiation or change of therapy; and a flare represents a cluster of symptoms of sufficient duration and intensity to require initiation, change, or increase in therapy. Using this working definition, evaluation of candidate domains will be conducted via Delphi exercise and further informed by patient focus groups. Validation of candidate definitions in appropriate RCT will be required.

[1]  A. Martini,et al.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial , 2008, The Lancet.

[2]  P. V. van Riel,et al.  Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study , 2008, Annals of the rheumatic diseases.

[3]  Y. Goekoop-Ruiterman,et al.  Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[4]  J. Hazes,et al.  Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[5]  J. Kirwan,et al.  Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis. , 2007, The Journal of rheumatology.

[6]  M. Suarez‐Almazor,et al.  Patient perspective: fatigue as a recommended patient centered outcome measure in rheumatoid arthritis. , 2007, The Journal of rheumatology.

[7]  Mahboob Rahman,et al.  Double-blinded infliximab dose escalation in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[8]  M. Dougados,et al.  Consensus statement on the use of rituximab in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[9]  M. Boers,et al.  Assessing single joints in arthritis clinical trials. , 2007, The Journal of rheumatology.

[10]  B. Rintelen,et al.  Lack of agreement between patients' and physicians' perspectives of rheumatoid arthritis disease activity changes , 2006, Scandinavian journal of rheumatology.

[11]  J. Smolen,et al.  [Measuring disease activity for rheumatoid arthritis]. , 2006, Zeitschrift fur Rheumatologie.

[12]  Mimi Y. Kim,et al.  Combined oral contraceptives in women with systemic lupus erythematosus. , 2005, The New England journal of medicine.

[13]  M. D. de Wit,et al.  Progress since OMERACT 6 on including patient perspective in rheumatoid arthritis outcome assessment. , 2005, The Journal of rheumatology.

[14]  J. Kremer,et al.  Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial* , 2005, Current medical research and opinion.

[15]  J. Daurès,et al.  Practices for managing a flare of long-standing rheumatoid arthritis: survey among French rheumatologists. , 2005, Clinical and experimental rheumatology.

[16]  D. Symmons,et al.  ICF Core Sets for rheumatoid arthritis. , 2004, Journal of rehabilitation medicine.

[17]  C. Gordon,et al.  Definition and treatment of lupus flares measured by the BILAG index. , 2003, Rheumatology.

[18]  P. Tugwell,et al.  MCID/Low Disease Activity State Workshop: low disease activity state in rheumatoid arthritis. , 2003, The Journal of rheumatology.

[19]  P. Tugwell,et al.  MCID/Low Disease Activity State Workshop: summary, recommendations, and research agenda. , 2003, The Journal of rheumatology.

[20]  J. Kirwan,et al.  Rheumatology outcomes: the patient's perspective. , 2003, The Journal of rheumatology.

[21]  E. Taal,et al.  Outcomes from the Patient Perspective Workshop at OMERACT 6. , 2003, The Journal of rheumatology.

[22]  D. Erkan,et al.  Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the “real world” , 2002, Annals of the rheumatic diseases.

[23]  P. V. van Riel,et al.  Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. , 2002, Rheumatology.

[24]  E. Giannini,et al.  Preliminary definition of disease flare in juvenile rheumatoid arthritis. , 2002, The Journal of rheumatology.

[25]  G. Stucki,et al.  Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity. , 2001, Arthritis and rheumatism.

[26]  Andre Peeters,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis , 2000 .

[27]  A. Silman,et al.  Breast-feeding and postpartum relapse in women with rheumatoid and inflammatory arthritis. , 2000, Arthritis and rheumatism.

[28]  A. Reiff,et al.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.

[29]  Mimi Y. Kim,et al.  Classification and definition of major flares in SLE clinical trials , 1999, Lupus.

[30]  D. Furst,et al.  Flare during drug withdrawal as a method to support efficacy in rheumatoid arthritis: amiprilose hydrochloride as an example in a double blind, randomized study. , 1998, The Journal of rheumatology.

[31]  D. Felson,et al.  Preliminary definition of improvement in juvenile arthritis. , 1997, Arthritis and rheumatism.

[32]  B. Dijkmans,et al.  Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis , 1996, The Lancet.

[33]  P. Gøtzsche,et al.  Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. , 1996, Scandinavian journal of rheumatology.

[34]  J. Kremer,et al.  Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. , 1987, The American journal of medicine.